Clin Mol Hepatol.
2017 Sep;23(3):219-221. 10.3350/cmh.2017.0045.
Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?
- Affiliations
-
- 1Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
- 2Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea. pindra@empal.com
- KMID: 2400667
- DOI: http://doi.org/10.3350/cmh.2017.0045
Abstract
- No abstract available.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Management of Antiviral Resistance in Chronic Hepatitis B
- Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B
- Efficacy of Tenofovir-based Rescue Therapy for Patients with Drug-resistant Chronic Hepatitis B
- Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
- Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B
